Drugs / Combotox
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01408160 | Apr 2013 → Jun 2018 | B-cell adult acute lymphocytic leukemia | Albert Einstein College of Medicine | Terminated | No outcome recorded |
| Phase 1 | NCT00450944 | Feb 2006 → Oct 2008 | leukemia | Albert Einstein College of Medicine | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Combotox | “Patients receive deglycosylated ricin A chain-conjugated anti-CD19 and anti-CD22 immunotoxins (Combotox) IV over 4 hours on days 1, 3, and 5 in the absence of disease...” NCT00450944 ↗1“Combotox is a mixture of two ricin-conjugated monoclonal antibodies (RFB4 and HD37) directed against CD19 and CD22, respectively, and has shown activity in pediatric and adult ALL.” PMID 22448921 ↗ Apr 2012 |
| Action | Deplete | “find cancer cells that express CD19 and CD22 and kill them without harming normal cells.” NCT00450944 ↗ |
| Modality | Protein / enzyme biologic | “deglycosylated ricin A chain-conjugated anti-CD19 and anti-CD22 immunotoxins (Combotox)” NCT00450944 ↗ |
| Route | Intravenous | “IV over 4 hours” NCT00450944 ↗ |